Dennis Priebat, M.D., is Director of Medical Oncology at MedStar Washington Hospital Center (MWHC) and serves as Program Director for the Hematology/Oncology Fellowship Program. In addition to his clinical responsibilities, he is an associate professor of Medicine at George Washington University School of Medicine, Washington, DC.
A specialist in soft-tissue sarcoma, Dr. Priebat has published chapters on this topic and also teaches courses for the Georgetown/Lombardi Cancer Center Hematology/Oncology fellowship program. He is board certified in Internal Medicine, with subspecialties in Medical Oncology and Hematology.
Dr. Priebat serves as a reviewer for Cancer, Oncology and Cancer Chemotherapy and Pharmacology and is an Expert Panel Reviewer for the American Society of Clinical Oncology. He is a frequent invited lecturer on topics ranging from osteogenic and soft-tissue sarcoma to new approaches to the treatment of advanced gastrointestinal cancer. His research has been published in Clinical Cancer Research, Clinical Nuclear Medicine, Hepatology International and other peer-reviewed journals.
Dr. Priebat is a fellow of the American College of Physicians and a member of the American Federation for Clinical Research, the American Society of Clinical Oncology, the American Society of Hematology and the Connective Tissue Oncology Society. Among other honors, he has been listed as a Top Doctor in Oncology/Hematology by Washingtonian Magazine and as an Outstanding Physician Specialist (Hematology/Oncology) by Washington Consumers' Checkbook. He is a member of the Cancer Committee at MWHC.
Dr. Priebat received his medical degree from the State University of New York, Stony Brook. He completed an internship and residency in Medicine at MWHC and clinical and research fellowships in Hematology/Oncology at the University of Utah, Salt Lake City.
Dr. Priebat's research interest include
- Medical oncology
- Soft-tissue and bone sarcoma
- Gastrointestinal stromal tumor (GIST)
- New treatment options
Efficacy of imatinib in aggressive fibromatosis
Aggressive fibromatoses are rare clonal neoplastic proliferations that can be aggressive despite surgery and/or radiation therapy. In this article, published in Clinical Cancer Research (2010;16:4884-4891), Dr. Priebat and colleagues report the outcomes of patients treated with imatinib in phase 2 of the Sarcoma Alliance for Research through Collaboration (SARC) Trial.
Monitoring of cardiac toxicity caused by doxorubicin
Doxorubicin is commonly used to treat solid tumors, such as breast, sarcoma, gynecologic and hematological malignancies. However, use of this drug is limited because of its effects on the heart. In this article, published in Clinical Nuclear Medicine (2009;34:762-767), Dr. Priebat and colleagues present an overview on the use of gated cardiac blood pool studies to assess the cardiac effects of doxorubicin.
- Research Areas